Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback